Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer.

ABSTRACT:

Background

Triple-negative breast cancer (TNBC) represents an aggressive breast cancer subtype with historically poor overall outcomes, due primarily to a lack of effective targeted agents. Chemotherapy has been the primary treatment approach, although immune checkpoint inhibitors (ICIs) are currently being investigated to improve patient outcomes. This review examines the clinical implications of current evidence on the use of ICIs for the treatment of metastatic TNBC.

Methods

Our systematic search identified two phase III and five phase I/II trials reporting on the efficacy of ICIs used as monotherapy or combined with chemotherapy for the treatment of metastatic TNBC.

Results

The phase III IMpassion 130 trial showed a significant improvement in median progression-fr

SUBMITTER: Simmons CE 

PROVIDER: S-EPMC7517981 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature